CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Novel R Shiny Tool for Survival Analysis With Time-Varying Covariate in Oncology Studies: Overcoming Biases and Enhancing Collaboration.
Novel R Shiny Tool for Survival Analysis With Time-Varying Covariate in Oncology Studies: Overcoming Biases and Enhancing Collaboration.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
我们推荐采用 TD Cox 模型和 Smith-Zee 曲线进行稳健的 TVC 分析。
**目的:**本研究关注一个有争议的问题:急性淋巴细胞白血病(ALL)患者接受CAR-T 细胞治疗后,造血细胞移植(HCT)的作用。由于患者可能在CAR-T 输注后的不同时间接受HCT,也可能始终未接受移植,因此CAR-T 治疗后的HCT应作为时变协变量(TVC)处理。**方法:**标准Cox模型和Kaplan-Meier(KM)曲线(朴素方法)假定基线时已知且固定TVC状态,可能导致有偏估计。里程碑分析是常用替代方法,但结果依赖所选里程碑时间。时变Cox模型更适合分析TVC,但其生存曲线较难可视化。新提出的Smith-Zee方法可根据时变Cox模型生成适当的生存曲线。
**结果:**为应对上述问题,研究团队开发了开源R Shiny工具,整合多种模型(朴素Cox、里程碑Cox和时变Cox)及曲线(朴素KM、里程碑KM、Smith-Zee和扩展KM),以便开展TVC分析。重新分析CAR-T 后HCT对无白血病生存期(LFS)的影响时,朴素Cox与时变Cox模型结果一致,而里程碑分析结果会随里程碑时间而变化。另一项关于慢性移植物抗宿主病与生存的分析显示,不同统计方法所得结果存在明显差异。模拟结果表明,当TVC在较晚阶段发生变化时,朴素方法的偏倚增加;若TVC较早发生变化且早于事件时间,则偏倚较小。**结论:**研究团队建议采用时变Cox模型和Smith-Zee曲线开展稳健的TVC分析。其R Shiny工具无需共享数据即可支持标准化分析,促进不同机构之间的协作,为肿瘤学研究中的生存分析提供实用工具。
Our study is motivated by evaluating the role of hematopoietic cell transplantation (HCT) after chimeric antigen receptor T-cell (CAR-T) therapy for ALL, a debated topic. Because patients may receive HCT at different times after CAR-T infusion or never, HCT post-CAR-T should be considered as a time-varying covariate (TVC).
Standard Cox models and Kaplan-Meier (KM) curves (na ve method) assume that TVC status is known and fixed at baseline, which can yield biased estimates. Landmark analysis is a popular alternative but depends on a chosen landmark time. Time-dependent (TD) Cox model is better suited for TVC although visualizing survival curves is complex. The newly proposed Smith-Zee method generates appropriate survival curves from TD Cox models.
To address these challenges, we developed an open-source R Shiny tool integrating multiple models (na ve Cox, landmark Cox, and TD Cox) and curves (na ve KM, landmark KM, Smith-Zee, and Extended KM) to facilitate TVC analysis. Reanalysis of post-CAR-T HCT's effect on leukemia-free survival (LFS) showed consistent results between na ve and TD Cox models, whereas landmark analyses varied by landmark time. A separate data analysis of chronic graft-versus-host disease and survival showed that substantial differences emerged across statistical methods. Simulations revealed increased bias in na ve methods when TVC changed late and minimal bias when TVC changes occurred early relative to time to events.
We recommend TD Cox models and Smith-Zee curves for robust TVC analysis. Our R Shiny tool supports standardized analyses without requiring data sharing, thereby promoting collaboration across different institutions and providing a practical tool to advance survival analysis in oncology research.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。